Related Experiment Videos
[Kidney transplantation and tumors]
1Klinika nefrologie a Patologicko-anatomické pracovistĕ Institutu klinické a experimentální medicíny, Praha.
Casopis Lekaru Ceskych
|September 26, 1994
Summary
Tumor development is a serious complication after kidney transplantation. This study found no significant difference in tumor frequency between azathioprine and cyclosporine A immunosuppression, but observed variations in organ-specific tumor types compared to global data.
Area of Science:
- Nephrology
- Oncology
- Immunology
Context:
- Organ transplantation, particularly kidney transplants, is associated with an increased risk of tumor development.
- Immunosuppressive therapy following transplantation is a key factor influencing oncogenesis.
- Comparing post-transplant tumor data with extensive international registries is crucial for understanding epidemiological trends.
Purpose:
- To assess the frequency and types of tumors in patients following renal transplantation.
- To compare these findings with data from the Cincinnati Tumor Registry (CTTR).
Summary:
- A cohort of 879 patients undergoing 989 renal transplantations between 1966 and 1992 showed a 3.64% incidence of tumors.
- Tumor types included skin (25%), native kidneys (21.9%), urinary tract (15.6%), GI tract (12.5%), and lymphomas (9%).
- No significant difference in tumor frequency was observed between azathioprine and cyclosporine A-based immunosuppression regimens.
Impact:
- Identifies specific tumor patterns in renal transplant recipients, highlighting skin, native kidney, and urinary tract tumors.
- Suggests potential differences in organ-specific tumor prevalence compared to the CTTR, particularly for lymphomas and common population cancers.
- Underscores the multifactorial nature of post-transplant malignancies and the need for ongoing surveillance.